These findings suggest that serum NfL levels could be used as a biomarker to assess the risk and severity of peripheral neuropathy in patients with gynecological tumors undergoing chemotherapy [211,212,216,217]. The gene discussed is NEFL; the disease is peripheral neuropathy.